Nrx pharmaceuticals files breakthrough therapy designation request for zyesami® (aviptadil) in patients at immediate risk of death from covid-19 despite treatment with remdesivir and other approved therapies

Radnor, pa., dec. 29, 2021 /prnewswire/ -- nrx pharmaceuticals (nasdaq: nrxp) announced today that it has filed a new breakthrough therapy designation (btd) request with the us food and drug administration (fda) focused on patients with critical covid-19 and respiratory failure who are at immediate risk of death despite treatment with remdesivir and other approved therapies.
NRXP Ratings Summary
NRXP Quant Ranking